Cytokinetics (CYTK) Short-term Investments (2010 - 2026)

Cytokinetics (CYTK) has reported Short-term Investments for 17 consecutive years, with $688.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 20.34% year-over-year to $688.7 million; the TTM figure through Mar 2026 stood at $688.7 million (down 20.34% YoY), while the FY2025 annual figure was $759.7 million, down 22.57% from the prior year.
• Short-term Investments fell to $688.7 million in Q1 2026 per CYTK's latest filing, from $759.7 million in the prior quarter.
• Across five years, Short-term Investments topped out at $981.2 million in Q4 2024 and bottomed at $439.5 million in Q3 2023.
• Historically, Short-term Investments has averaged $682.9 million across 5 years, with a median of $717.0 million in 2022.
• Annual changes were most pronounced in 2023 — Short-term Investments slumped 42.27% — and 2024, when it surged 119.5%.
• Cytokinetics' Short-term Investments stood at $717.0 million in 2022, then slumped by 30.01% to $501.8 million in 2023, then surged by 95.53% to $981.2 million in 2024, then retreated by 22.57% to $759.7 million in 2025, then declined by 9.35% to $688.7 million in 2026.
• Business Quant data shows CYTK's Short-term Investments at $688.7 million in Q1 2026, $759.7 million in Q4 2025, and $737.1 million in Q3 2025.